A minority of patients with primary central nervous system lymphoma achieve a complete response to therapy andmost patients have a poor prognosis.A recent randomised phase II trial demonstrated that the addition of high-dose cytarabine to high-dosemethotrexate increases the complete response rate and improves patient outcome.
Leave a Reply